JP2024123089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024123089A5 JP2024123089A5 JP2024096313A JP2024096313A JP2024123089A5 JP 2024123089 A5 JP2024123089 A5 JP 2024123089A5 JP 2024096313 A JP2024096313 A JP 2024096313A JP 2024096313 A JP2024096313 A JP 2024096313A JP 2024123089 A5 JP2024123089 A5 JP 2024123089A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163215435P | 2021-06-26 | 2021-06-26 | |
| US63/215,435 | 2021-06-26 | ||
| US202163294590P | 2021-12-29 | 2021-12-29 | |
| US63/294,590 | 2021-12-29 | ||
| US202263350495P | 2022-06-09 | 2022-06-09 | |
| US63/350,495 | 2022-06-09 | ||
| JP2023579070A JP7511097B1 (ja) | 2021-06-26 | 2022-06-23 | Ｈｅｒ２変異阻害薬 |
| PCT/IB2022/055827 WO2022269531A1 (en) | 2021-06-26 | 2022-06-23 | Her2 mutation inhibitors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579070A Division JP7511097B1 (ja) | 2021-06-26 | 2022-06-23 | Ｈｅｒ２変異阻害薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024123089A JP2024123089A (ja) | 2024-09-10 |
| JP2024123089A5 true JP2024123089A5 (enExample) | 2024-10-11 |
Family
ID=82404061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579070A Active JP7511097B1 (ja) | 2021-06-26 | 2022-06-23 | Ｈｅｒ２変異阻害薬 |
| JP2024096313A Pending JP2024123089A (ja) | 2021-06-26 | 2024-06-14 | Ｈｅｒ２変異阻害薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579070A Active JP7511097B1 (ja) | 2021-06-26 | 2022-06-23 | Ｈｅｒ２変異阻害薬 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12447153B2 (enExample) |
| EP (1) | EP4359082A1 (enExample) |
| JP (2) | JP7511097B1 (enExample) |
| KR (1) | KR20240027048A (enExample) |
| AU (1) | AU2022297733B2 (enExample) |
| CA (1) | CA3225045A1 (enExample) |
| CL (1) | CL2023003774A1 (enExample) |
| CO (1) | CO2023017970A2 (enExample) |
| CR (1) | CR20230604A (enExample) |
| DO (1) | DOP2023000281A (enExample) |
| IL (1) | IL309252A (enExample) |
| MX (1) | MX2023015139A (enExample) |
| PE (1) | PE20250118A1 (enExample) |
| TW (1) | TWI850685B (enExample) |
| UY (1) | UY39830A (enExample) |
| WO (1) | WO2022269531A1 (enExample) |
| ZA (1) | ZA202311377B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2023081637A1 (en) | 2021-11-02 | 2023-05-11 | Enliven Therapeutics, Inc. | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 |
| WO2024027695A1 (zh) * | 2022-08-04 | 2024-02-08 | 微境生物医药科技(上海)有限公司 | 作为her2抑制剂的化合物 |
| WO2025051148A1 (zh) * | 2023-09-05 | 2025-03-13 | 北京鞍石生物科技股份有限公司 | 含氮杂芳基化合物及其制备方法和应用 |
| WO2025202889A1 (en) * | 2024-03-28 | 2025-10-02 | Array Biopharma Inc. | Her2 mutation inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1660090B1 (en) | 2003-08-14 | 2012-11-21 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| PL2090575T3 (pl) * | 2005-11-15 | 2011-09-30 | Array Biopharma Inc | Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy |
| JP7333313B2 (ja) | 2017-09-01 | 2023-08-24 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 窒素含有複素環化合物、製造方法、中間体、組成物および使用 |
| WO2021127397A1 (en) * | 2019-12-19 | 2021-06-24 | Black Diamond Therapeutics, Inc. | Nitrogen heterocyclic compounds and methods of use |
| CN115052881B (zh) | 2020-02-03 | 2024-07-09 | 勃林格殷格翰国际有限公司 | 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶 |
| US20230126204A1 (en) | 2020-02-03 | 2023-04-27 | Boehringer Ingelheim International Gmbh | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| WO2022006386A1 (en) | 2020-07-02 | 2022-01-06 | Enliven Therapeutics, Inc. | Alkyne quinazoline derivatives as inhibitors of erbb2 |
| EP4323356A1 (en) * | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2022266458A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-heterocycloalkyl-quinazoline derivatives and uses thereof |
| EP4476211A1 (en) * | 2022-02-09 | 2024-12-18 | Enliven Inc. | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 |
-
2022
- 2022-06-23 WO PCT/IB2022/055827 patent/WO2022269531A1/en not_active Ceased
- 2022-06-23 PE PE2023003456A patent/PE20250118A1/es unknown
- 2022-06-23 CA CA3225045A patent/CA3225045A1/en active Pending
- 2022-06-23 KR KR1020247002985A patent/KR20240027048A/ko active Pending
- 2022-06-23 EP EP22738011.0A patent/EP4359082A1/en active Pending
- 2022-06-23 AU AU2022297733A patent/AU2022297733B2/en not_active Expired - Fee Related
- 2022-06-23 IL IL309252A patent/IL309252A/en unknown
- 2022-06-23 MX MX2023015139A patent/MX2023015139A/es unknown
- 2022-06-23 CR CR20230604A patent/CR20230604A/es unknown
- 2022-06-23 JP JP2023579070A patent/JP7511097B1/ja active Active
- 2022-06-24 TW TW111123585A patent/TWI850685B/zh active
- 2022-06-24 UY UY0001039830A patent/UY39830A/es unknown
- 2022-06-25 US US17/849,621 patent/US12447153B2/en active Active
-
2023
- 2023-12-11 ZA ZA2023/11377A patent/ZA202311377B/en unknown
- 2023-12-18 CL CL2023003774A patent/CL2023003774A1/es unknown
- 2023-12-20 CO CONC2023/0017970A patent/CO2023017970A2/es unknown
- 2023-12-21 DO DO2023000281A patent/DOP2023000281A/es unknown
-
2024
- 2024-06-14 JP JP2024096313A patent/JP2024123089A/ja active Pending